Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
Open Access
- 16 September 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (9) , 1155
Abstract
Somatostatin receptor subtype 2 (SSTR2) has become an essential target for radionuclide therapy of neuroendocrine tumors (NETs). JR11 was introduced as a promising antagonist peptide to target SSTR2. However, due to its rapid blood clearance, a better pharmacokinetic profile is necessary for more effective treatment. Therefore, two JR11 analogs (8a and 8b), each carrying an albumin binding domain, were designed to prolong the blood residence time of JR11. Both compounds were labeled with lutetium-177 and evaluated via in vitro assays, followed by in vivo SPECT/CT imaging and ex vivo biodistribution studies. [177Lu]Lu-8a and [177Lu]Lu-8b were obtained with high radiochemical purity (>97%) and demonstrated excellent stability in PBS and mouse serum (>95%). [177Lu]Lu-8a showed better affinity towards human albumin compared to [177Lu]Lu-8b. Further, 8a and 8b exhibited binding affinities 30- and 48-fold lower, respectively, than that of the parent peptide JR11, along with high cell uptake and low internalization rate. SPECT/CT imaging verified high tumor accumulation for [177Lu]Lu-8a and [177Lu]Lu-JR11 at 4, 24, 48, and 72 h post-injection, but no tumor uptake was observed for [177Lu]Lu-8b. Ex vivo biodistribution studies revealed high and increasing tumor uptake for [177Lu]Lu-8a. However, its extended blood circulation led to an unfavorable biodistribution profile for radionuclide therapy.Keywords
Funding Information
- KWF Kankerbestrijding (12259)
This publication has 30 references indexed in Scilit:
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor AntagonistJournal of Nuclear Medicine, 2016
- Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine XenograftsJournal of Nuclear Medicine, 2016
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical ModelsJournal of Nuclear Medicine, 2015
- Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogsApplied Radiation and Isotopes, 2014
- DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in MiceJournal of Nuclear Medicine, 2012
- Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal ModificationsJournal of Nuclear Medicine, 2012
- Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In VitroJournal of Nuclear Medicine, 2011
- First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is FeasibleJournal of Nuclear Medicine, 2011
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences, 2006